Andrew Bellinger M.D., Ph.D.
Net Worth

Last updated:

What is Andrew Bellinger M.D., Ph.D. net worth?

The estimated net worth of Dr. Andrew Bellinger M.D., Ph.D. is at least $5,612,033 as of 14 Dec 2022. He owns shares worth $74,245 as insider, has earned $3,587,428 from insider trading and has received compensation worth at least $1,950,360 in Verve Therapeutics, Inc..

What is the salary of Andrew Bellinger M.D., Ph.D.?

Dr. Andrew Bellinger M.D., Ph.D. salary is $487,590 per year as Chief Scientific Officer & Chief Medical Officer in Verve Therapeutics, Inc..

How old is Andrew Bellinger M.D., Ph.D.?

Dr. Andrew Bellinger M.D., Ph.D. is 47 years old, born in 1978.

What stocks does Andrew Bellinger M.D., Ph.D. currently own?

As insider, Dr. Andrew Bellinger M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Verve Therapeutics, Inc. (VERV) Chief Scientific Officer & Chief Medical Officer 6,629 $11.2 $74,245

What does Verve Therapeutics, Inc. do?

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

VERV logo
VERV
Verve Therapeutics, Inc.
$11.2

Andrew Bellinger M.D., Ph.D. insider trading

Verve Therapeutics, Inc.

Dr. Andrew Bellinger M.D., Ph.D. has made 8 insider trades between 2021-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 40,000 units of VERV stock on 23 Sep 2022. As of 14 Dec 2022 he still owns at least 6,629 units of VERV stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 36,000 $2.87 $103,320
Option
Stock Option (right to buy) 36,000 $2.87 $103,320
Sale
Common Stock 865 $22.95 $19,852
Sale
Common Stock 10,000 $39.9 $399,000
Option
Common Stock 10,000 $1.48 $14,800
Option
Stock Option (right to buy) 10,000 $1.48 $14,800
Option
Common Stock 20,000 $1.48 $29,600
Option
Stock Option (right to buy) 20,000 $1.48 $29,600
Option
Common Stock 40,000 $1.48 $59,200
Sale
Common Stock 3,202 $36.03 $115,381
Option
Stock Option (right to buy) 40,000 $1.48 $59,200
Sale
Common Stock 36,798 $35.31 $1,299,301
Sale
Common Stock 6,632 $34.67 $229,905
Option
Stock Option (right to buy) 20,000 $1.39 $27,800
Option
Common Stock 20,000 $1.39 $27,800
Sale
Common Stock 20,000 $34.9 $698,000
Option
Stock Option (right to buy) 10,000 $1.48 $14,800
Option
Common Stock 10,000 $1.48 $14,800
Sale
Common Stock 10,000 $24.9 $249,000
Sale
Common Stock 15,000 $38.47 $576,990
Option
Common Stock 15,000 $1.48 $22,200
Option
Stock Option (right to buy) 15,000 $1.48 $22,200
Purchase
Common Stock 5,000 $19 $95,000

Verve Therapeutics key executives

Verve Therapeutics, Inc. executives and other stock owners filed with the SEC: